Overall, the incidence of grade 3/4 toxicity was 65% in the Taxotere arm (TPF) compared to 62% in the group receiving cisplatin and fluorouracil (PF). Patients treated with TPF had more febrile neutropenia (12% vs 7%), neutropenic infection (12% vs 8%), and grade 3/4 neutropenia (83% vs. 56%), dizziness (4% vs. 2%), alopecia (4% vs 1%) and diarrhea (7% vs. 3%) than those in the PF group. Patients in the PF group had more grade 3/4 thrombocytopenia (11% vs. 4%), stomatitis (27% vs. 21%), lethargy (10% vs. 5%) and vomiting (10% vs. 8%). The incidence of other grade 3/4 events was similar between the two groups, such as nausea, anorexia and constipation.
Head and Neck Cancer, a Deadly Disease
More than 640,000 people worldwide are diagnosed with head and neck cancer each year, and more than 350,000 die from the disease annually. Head and neck cancer is a group of many related diseases that mostly begin in the cells that line the mucosal surfaces in the head and neck area such as the mouth, nose and throat. The term encompasses cancers of the oral cavity, paranasal sinuses and nasal cavity, tongue, tonsils, pharynx, larynx, and lymph nodes in the upper part of the neck.
Indications and Usage
Taxotere(R) is indicated for the treatment of patients with locally advanced or metastatic breast cancer after failure of prior chemotherapy.
Taxotere(R) in combination with doxorubicin and cyclophosphamide is indicated for the adjuvant treatment of patients with operable node-positive breast cancer.
Non-Small Cell Lung Cancer (NSCLC)
Taxotere(R), as a single agent, is indicated for the treatment of patients with locally advanced or metastatic NSCLC after failure of prior platinum- based chemotherapy.
Taxotere(R) in combination with cisplatin is indicated for the
treatment of patients with unresecta
Copyright©2007 PR Newswire.
All rights reserved